Adaptive Biotechnologies (ADPT) Tops Q1 EPS by 12c

Adaptive Biotechnologies (NASDAQ: ADPT) reported Q1 EPS of ($0.29), $0.12 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $38.4 million versus the consensus estimate of $27.75 million.

“We started the year strong with revenue increasing 84% year over year, driven by growth in both our sequencing and development revenue categories,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “I am encouraged by the solid momentum across all areas of our business as we continue to capitalize on the multiple opportunities originating from our platform.”

GUIDANCE:

Adaptive Biotechnologies sees FY2021 revenue of $145-155 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• American Outdoor Brands (AOUT) Tops Q4 EPS by 14c
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook